Medifast (NYSE:MED) Issues Q2 2026 Earnings Guidance

Medifast (NYSE:MED) updated its second quarter 2026 earnings guidance on Monday. The company provided earnings per share guidance of -1.000–0.500 for the period, compared to the consensus earnings per share estimate of -0.430. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $75.0 million. Medifast also updated its FY 2026 guidance to -2.750–1.550 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Stephens lowered their price objective on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 19th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Medifast presently has an average rating of “Reduce” and a consensus price target of $12.00.

Medifast Stock Performance

NYSE MED traded down $0.47 during mid-day trading on Wednesday, reaching $12.55. 35,169 shares of the stock were exchanged, compared to its average volume of 245,890. The stock has a market capitalization of $138.44 million, a PE ratio of -6.85 and a beta of 0.55. Medifast has a 1-year low of $9.22 and a 1-year high of $15.46. The business’s fifty day simple moving average is $10.46 and its 200 day simple moving average is $11.10.

Medifast (NYSE:MED) last released its quarterly earnings data on Monday, May 4th. The specialty retailer reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.36. Medifast had a negative return on equity of 4.73% and a negative net margin of 5.78%.The business had revenue of $76.04 million during the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. On average, analysts anticipate that Medifast will post -2 EPS for the current year.

Insider Transactions at Medifast

In other Medifast news, CEO Daniel R. Chard purchased 17,678 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was acquired at an average cost of $10.11 per share, with a total value of $178,724.58. Following the acquisition, the chief executive officer owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 3.70% of the stock is owned by insiders.

Institutional Trading of Medifast

A number of large investors have recently modified their holdings of MED. Lido Advisors LLC acquired a new position in shares of Medifast during the third quarter worth approximately $4,521,000. Steamboat Capital Partners LLC acquired a new position in shares of Medifast during the 4th quarter valued at $2,952,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after buying an additional 181,618 shares during the period. Bank of America Corp DE lifted its holdings in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock valued at $5,569,000 after buying an additional 107,854 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Medifast during the third quarter worth about $867,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.